NCT06557889
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06557889
Title Reduction in the Number of Chemotherapy Cycles in Combination With Pembrolizumab in First-line Treatment of PD-L1-positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinomas (REDUCE)
Acronym REDUCE
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Institut Claudius Regaud
Indications
Therapies
Age Groups: adult | senior
Covered Countries FRA

Facility Status City State Zip Country Details
Institut Sainte Catherine NOT_YET_RECRUITING Avignon France Details
Chu Bordeaux - Hopital Saint André RECRUITING Bordeaux France Details
Centre Jean Perrin NOT_YET_RECRUITING Clermont-Ferrand France Details
Centre Oscar Lambret NOT_YET_RECRUITING Lille France Details
Chu Limoges RECRUITING Limoges France Details
Centre Hospitalier Regional de Marseille RECRUITING Marseille France Details
CHU de Nantes NOT_YET_RECRUITING Nantes France Details
Centre Antoine Lacassagne RECRUITING Nice France Details
Chu de Nimes RECRUITING Nîmes France Details
CHU Poitiers RECRUITING Poitiers France Details
Centre Eugène Marquis NOT_YET_RECRUITING Rennes France Details
Clinique Pasteur RECRUITING Toulouse France Details
IUCT-O RECRUITING Toulouse France Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field